Truist raises target for Jazz Pharmaceuticals stock to USD 286.00

Published on 10/08/2026 at 16:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 1.21 billion in the second quarter, up 16.00 percent. Jazz Pharmaceuticals stock costs EUR 195.95 on October 8, 2026 after EUR 206.50.

Key points in brief

Truist raised its Jazz Pharmaceuticals price target from USD 281.00 to USD 286.00 on October 7, 2026.
Second-quarter 2026 revenue reached USD 1.21 billion, up 16.00 percent year over year.
Jazz stock was trading at EUR 195.95 at Lang & Schwarz on October 8, 2026, down 5.11 percent versus EUR 206.50.
Jazz completed the USD 820.00 million Actio Biosciences acquisition on September 15, 2026.
The next reported earnings date is November 11, 2026.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals stock was trading at EUR 195.95 at Lang & Schwarz on October 8, 2026 at 4:41 p.m. CEST, down 5.11 percent versus the prior close of EUR 206.50. The latest analyst action came from Truist, which raised its price target from USD 281.00 to USD 286.00 on October 7, 2026, while maintaining a Buy rating, according to Markets Insider.

Three events shape the story

On September 9, 2026, Investing.com reported that Jazz had delivered second-quarter revenue of USD 1.21 billion, up 16.00 percent year over year. On September 15, 2026, Jazz completed its USD 820.00 million upfront acquisition of Actio Biosciences, according to Jazz Pharmaceuticals. On October 7, 2026, Truist raised its target to USD 286.00 from USD 281.00, keeping its Buy rating, according to Markets Insider.

What does the pipeline bet add?

Actio adds ABS-1230, a clinical-stage oral candidate for KCNT1-related epilepsy, to Jazz's rare-disease pipeline. The acquisition gives the company a new asset in pediatric epilepsy, but the candidate still depends on clinical and regulatory execution before it can contribute revenue, a risk described in the Jazz Pharmaceuticals release dated September 15, 2026.

Revenue breadth supports the valuation

The second-quarter result was more than a single-product story. Investing.com reported that Epidiolex generated USD 292.00 million in second-quarter revenue, up 16.00 percent year over year, while Modeyso generated USD 48.00 million. The same source reported that Ziihera's peak sales estimate had risen to USD 3.00 billion to USD 5.00 billion from more than USD 2.00 billion previously.

Upcoming dates and the stock

The next reported earnings date is November 11, 2026, according to the event information published by Investing.com. The ACTION study for Modeyso is scheduled to read out in the first half of 2027, as described in the Wells Fargo conference transcript.

At Lang & Schwarz, Jazz Pharmaceuticals stock was trading at EUR 195.95 on October 8, 2026 at 4:41 p.m. CEST, down 5.11 percent versus the prior close of EUR 206.50. The further course of trading is shown by the continuously updated real-time quote of Jazz Pharmaceuticals stock.